Table 3 The summary of data collected through the literature search: study design, stent type, drug eluted and the concentration (µg/mm2), scaffold material used, polymer used, stent strut thickness (µm), number of participants, gender (% male), and age (years) using means and standard deviations (SD), as well as interquartile ranges (IQR)
From: Critical evaluation of stents in coronary angioplasty: a systematic review
Study | Study design | Stent type | Drug eluted (µg/mm2) | Scaffold used | Polymer used | Strut thickness (µm) | Participant number | Male (%) | Age (year) (mean ± SD) |
|---|---|---|---|---|---|---|---|---|---|
[24] | Prospective, single-arm, open-label trial | BRS | Sirolimus (3.9) | Cobalt–chromium alloy | PDDLA | 80 | 60 | 73.3 | 67.2 ± 9.9 |
[25] | Cohort | BRS | Everolimus (not given) | – | PLL and PDLL | (Not given) | 14 | 79.0 | 59 ± 10 |
[26] | Retrospective, autopsy study | DES | Sirolimus and paclitaxel (not given) | Stainless steel | – | (Not given) | 80 | 67.5 | 60.0 ± 12.0 |
[27] | Cohort | BRS | Everolimus (not given) | – | Semi-crystalline PLA | 150 | 90 | 79.0 | 59.0 ± 10.0 |
[28] | RCT | PES | TAXUS Liberte-Paclitaxel (3.9) | Stainless steel | Durable | (Not given) | 19 | 78.9 | 63.1 ± 8.2 |
JACTAX (HD)-Paclitaxel (9.2) | Stainless steel | Polylactide | 98 | 21 | 75.0 | 64.1 ± 8.7 | |||
JACTAX (LD)-Paclitaxel (5.0) | Stainless steel | Polylactide | 98 | 20 | 90.5 | 66.0 ± 6.6 | |||
[29] | RCT | BMS | – | Stainless steel | – | (Not given) | 32 | 75.9 | 68.6 (IQR = 58.4–71.9) |
PES | TAXUS express-paclitaxel (not given) | Stainless steel | SIBS | 140 | 93 | 74.2 | 60.4 (IQR = 53.1–69.1) | ||
[30] | Prospective, single-arm trial | PES | Paclitaxel (not given) | (Not given) | (Not given) | (Not given) | 30 | 76.0 | 67.8 ± 9.6 |
[31] | Cohort | BES | Biolimus (not given) | Stainless steel | PLA | 112 | 369 | 78.6 | 62.3 ± 0.7 |
EES/ZES | Everolimus/Zotarolimus | Cobalt–chromium alloy | Biocompatible | 81 | 1178 | 79.4 | 62.8 ± 0.3 | ||
[23] | RCT | SES | Sirolimus (1.4) | Silicone-carbide | PLLA | 60–80 | 1261 | 74.9 | 66.1 ± 10.7 |
BES | Biolimus (15.6) | Stainless steel | PLLA | 120 | 1264 | 75.2 | 64.8 ± 10.8 | ||
[32] | RCT | BES | Biolimus (not given) | Stainless steel | PLA | 112 | 765 | 80.0 | 62.0 ± 11.0 |
EES | Everolimus (not given) | Cobalt–chromium alloy | Durable | 81 | 765 | 78.0 | 62.0 ± 11.0 | ||
BMS | – | Silicone-carbide | – | 60 | 761 | 75.0 | 63.0 ± 11.0 | ||
[33] | RCT | DES | Ridaforolimus (1.1) | Cobalt alloy | PBMA | 87 | 958 | 78.3 | 63.7 ± 10.2 |
ZES | Zotarolimus (1.6) | Cobalt alloy | Biocompatible | 91 | 961 | 81.9 | 63.1 ± 10.3 | ||
[34] | RCT | EES | Everolimus (1.0) | Platinum–chromium alloy | PLGA | 74–81 | 846 | 70.6 | 63.5 ± 10.4 |
EES | Everolimus (1.0) | Platinum–chromium alloy | PBMA | 81–84 | 838 | 72.7 | 63.9 ± 10.5 | ||
[35] | Retrospective, autopsy study | DES | Sirolimus, paclitaxel or everolimus (not given) | (Not given) | (Not given) | (Not given) | 82 | 65.9 | 58.3 ± 11.0 |
[36] | Cohort | SES | Sirolimus (not given) | (Not given) | (Not given) | 140 | 32 | 93.8 | 65.2 ± 8.2 |
[37] | RCT | SES | Sirolimus (1.8) | Stainless steel | PBMA | 140 | 250 | 78.0 | 67.4 (IQR = 59.0–75.4) |
BMS | – | (Not given) | – | 76 | 250 | 78.0 | 66.7 (IQR = 59.9–74.7) | ||
[38] | Cohort | BRS | Everolimus (1.0) | PLLA | PLLA | 157 | 56 | 71.0 | 60.0 ± 8.0 |
[39] | RCT | BMS | – | Cobalt–chromium alloy | – | 65 | 161 | 72.7 | 69.1 ± 12.7 |
BMS | – | Stainless steel | – | 80 | 222 | 75.7 | 69.8 ± 11.5 | ||
[40] | RCT | SES | Sirolimus (2.0) | (Not given) | PE/PLA | (Not given) | 46 | 85.0 | 66.8 ± 9.5 |
PES | Paclitaxel (0.25) | (Not given) | PE/PLA | (Not given) | 45 | 89.0 | 67.3 ± 8.6 | ||
[21] | Prospective, single-arm trial | BRS | Sirolimus (1.4) | Absorbable magnesium mixed with rare earth metals | PLLA | 150 | 184 | 63.0 | 65.5 ± 10.8 |
[22] | RCT | BRS | Everolimus (not given) | PLLA | PLLA | 156 | 1296 | 72.0 | 63·1 ± 10·1 |